Go to the page content

Sharing clinical study information

Novo Nordisk is committed to sharing information about all clinical studies and their results.

Information and results are shared

  • Irrespective if the results are positive or negative.
  • At the beginning of the study (information).
  • At the end of the study (results).
  • At multiple platforms like public registries:

    • US: clinicaltrials.gov
    • EU: Clinical Trials in the European Union - EMA euclinicaltrials.eu
    • Clinical Trails Information System (CTIS)
    • This website
  • After the data has been ”redacted”. (Redaction is a process to ensure that any personal data and/or commercially confi dential information is removed and that the published document follows regulatory guidance, data protection laws and company policies.) With researchers who have interest in detailed datasets.
  • With researchers who have interest in detailed datasets.
  • In accordance with international and national laws and guidelines. Key references here are:

    • European Union Legislation
    • US Food and Drug Administration Acts
    • IFPMEA Joint Position
    • WMA Declaration of Helsinki

Access to anonymized clinical study datasets

Novo Nordisk A/S supports secondary use of data from Novo Nordisk Sponsored clinical studies for conducting further legitimate scientifi c research as set out in the joint EFPIA-PhRMA Principles for Responsible Clinical Trial Data Sharing. 

If you are a researcher, you can request access to anonymized patient level data and study protocols from studies which have been completed after 2001, if product indications have obtained marketing authorization in both the EU and US.

You can as data requestor submit a scientifi c research proposal to document the legitimacy of your research project and the qualifi cations of your research team.

Access to individual study participant level data can be considered if the data can be sufficiently anonymized to protect personal identifi able information, safeguarding study participants’ privacy, if patients’ informed consent which was given in relation to their participation in the clinical study, can be respected.

Novo Nordisk A/S current data sharing platform will be decommissioned by the end of 2024, and we are investigating alternative data sharing methods on high priority. More information about this will be disclosed on this website when we have news to share. If you need further information, please contact us using our mailbox irb-secretariat@novonordisk.com.

Completed clinical trials

Novo Nordisk is committed to sharing information about clinical studies.